6-K

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

dated November 27, 2012

Commission File Number 0-51504

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

N/A

(Translation of Registrant’s Name)

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x               Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o                            No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  Not applicable.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 27, 2012
	GENETIC TECHNOLOGIES LIMITED
	By:	/s/ Thomas Howitt
		Name:	Thomas Howitt
		Title:	Chief Financial Officer

2

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	Presentation to Annual Meeting, November 27, 2012
99.2	ASX Announcement, November 27, 2012 (Results from Annual Meeting)
99.3	ASX Announcement, November 27, 2012 (Resignations)

3

EX-99.1

Exhibit 99.1

EX-99.2

Exhibit 99.2

ASX ANNOUNCEMENT

November 27th, 2012

Results from 2012 Annual General Meeting

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) advises that the 2012 Annual General Meeting of shareholders was held at 11.00 am today (Melbourne time).

Resolutions 2 (election of Greg Brown), 3 (re-election of Dr. Mal Brandon) and 5 (adoption of remuneration report) that were put before the shareholders were passed on a show of hands.  Details of the proxy votes received by the Company in respect of all six resolutions is contained in Table 1 to this announcement on the attached page.

A poll was conducted in respect of Resolutions 1 (election of Dr. Mel Bridges), 4 (re-election of Huw Jones) and 6 (approval of additional placement capacity) and those resolutions were not passed.  Details of the votes cast in the poll in respect of those three resolutions is contained in Table 2 to this announcement on the attached page.

FOR INFORMATION REGARDING THIS ANNOUNCEMENT PLEASE CONTACT

Thomas G. Howitt

Company Secretary

Genetic Technologies Limited (ABN 17 009 212 328)

Phone: +61 3 8412 7000

Table 1 - Proxy results for 2012 Annual General Meeting

Description of Resolution	For		Against		Abstain		In favour of Chairman		In favour of others
Consideration of financial statements	NO VOTE REQUIRED
1. Election of Dr. Mel Bridges
Numbers of votes received	25,468,292		139,359		252,642		277,200		165,663,557
Percentage of votes cast	13.28	%	0.07	%	0.13	%	0.14	%	86.38	%
2. Election of Mr. Greg Brown
Numbers of votes received	25,517,592		56,565		286,136		277,200		165,663,557
Percentage of votes cast	13.30	%	0.03	%	0.15	%	0.14	%	86.38	%
3. Re-election of Dr. Mal Brandon
Numbers of votes received	25,408,292		165,865		286,136		277,200		165,663,557
Percentage of votes cast	13.25	%	0.08	%	0.15	%	0.14	%	86.38	%
4. Re-election of Mr. Huw Jones
Numbers of votes received	25,097,892		476,265		286,136		277,200		165,663,557
Percentage of votes cast	13.09	%	0.24	%	0.15	%	0.14	%	86.38	%
5. Adoption of Remuneration Report
Numbers of votes received	24,942,697		680,854		236,742		277,200		165,663,557
Percentage of votes cast	13.00	%	0.36	%	0.12	%	0.14	%	86.38	%
6. Approval of placement capacity
Numbers of votes received	12,860,691		12,995,102		4,500		277,200		165,663,557
Percentage of votes cast	6.71	%	6.77	%	0.00	%	0.14	%	86.38	%

Note:      The Company currently has a total of 474,971,819 ordinary shares on issue and 3,002 registered shareholders.

Table 2 - Poll results for 2012 Annual General Meeting

Description of Resolution	For		Against		Abstain		Result
1. Election of Dr. Mel Bridges
Numbers of votes received	28,140,491		168,598,517		752,642		Resolution not passed
Percentage of votes cast	14.25	%	85.37	%	0.38	%
4. Re-election of Mr. Huw Jones
Numbers of votes received	27,535,219		168,672,408		1,284,023		Resolution not passed
Percentage of votes cast	13.94	%	85.41	%	0.65	%
6. Approval of placement capacity
Numbers of votes received	14,832,589		182,654,561		4,500		Resolution not passed
Percentage of votes cast	7.51	%	92.49	%	0.00	%

Genetic Technologies Limited· Website: www.gtglabs.com · Email: info@gtglabs.com     ABN 17 009 212 328

Registered Office· 60-66 Hanover Street Fitzroy Victoria 3065 Australia · Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia

Phone +61 3 8412 7000 · Fax +61 3 8412 7040

EX-99.3

Exhibit 99.3

ASX ANNOUNCEMENT

November 27th, 2012

Resignations

Following today’s Annual General Meeting in Melbourne, the Board of Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) announces the outcome of the AGM - directors Dr. Mel Bridges and Mr. Huw Jones will be leaving the Board, and Mr. Greg Brown has resigned effective November 27th, 2012.

The Board also announces the immediate resignation of Dr. Paul MacLeman as CEO and also accepts the resignation of Dr. David Sparling, VP Legal and Corporate Development.

Dr. Bridges said it is regrettable that a company with the potential of GTG was unable to reach middle ground with its major shareholder.

Genetic Technologies Limited (ABN 17 009 212 328)

Phone: +61 3 8412 7000